Histological healing: should it be considered as a new outcome for ulcerative colitis?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Histological healing: should it be considered as a new outcome for ulcerative colitis?

Published:2020-01-10 Issue:4 Volume:20 Page:407-412
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Dal Buono Arianna¹,Roda Giulia¹,Argollo Marjorie¹²^ORCID,Peyrin-Biroulet Laurent³,Danese Silvio¹^ORCID

Affiliation:

1. IBD Center, Department of Gastroenterology, Humanitas Research Hospital, Milan, Italy

2. Gastroenterology, Universidade Federal de São Paulo, São Paulo, Brazil

3. Department of Gastroenterology and Inserm U954, University Hospital of Nancy, University of Lorraine, Nancy, France

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2020.1701652

Reference39 articles.

1. Ulcerative colitis

2. Clinical Trials in Ulcerative Colitis: A Historical Perspective

3. A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review

4. Which evidence for a treat to target strategy in ulcerative colitis?

5. Histologic Remission: The Ultimate Therapeutic Goal in Ulcerative Colitis?

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. To STRIDE or not to STRIDE: a critique of “treat to target” in ulcerative colitis;Expert Review of Gastroenterology & Hepatology;2024-08-28

2. Ulcerative colitis: the healing power of macrophages;Tissue Barriers;2024-08-10

3. Absence of Paneth Cell Metaplasia to Predict Clinical Relapse in Ulcerative Colitis with Endoscopically Quiescent Mucosa;Digestive Diseases and Sciences;2024-08-07

4. Mesalazine dose modification based on faecal calprotectin levels in patients with ulcerative colitis in clinical remission;Gastroenterología y Hepatología (English Edition);2024-06

5. Comprehensive overview of novel chemical drugs for ulcerative colitis: focusing on phase 3 and beyond;Expert Opinion on Pharmacotherapy;2024-03-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3